top of page
Search

The Long Tail of COVID: The XFG Variant, Microclots, and the Economic Fallout

Virus labeled XFG with digital graphs in a lab. Neurons connect to declining markets, gears, and an office. "Help Wanted" sign present.

1. Introduction: The Complex Respiratory Landscape of Winter 2025-2026

As the United States progresses through the winter of 2025-2026, the public health narrative regarding Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has fundamentally shifted. No longer defined by the singular, catastrophic waves of mortality that characterized the early 2020s, the pandemic has transitioned into a complex endemic phase. This new era is marked by predictable seasonal surges, a rapid and relentless evolution of viral lineages, and a persistent, accruing burden of chronic post-acute sequelae known as Long COVID.

Current epidemiological data indicates that the nation is navigating a "tripledemic" dynamic, where COVID-19 co-circulates with a resurgent Influenza and steady levels of Respiratory Syncytial Virus (RSV).1 As of January 2026, hospitalizations for respiratory viruses are climbing, driven by holiday travel, indoor gatherings, and the emergence of immune-evasive variants.2 The Centers for Disease Control and Prevention (CDC) has projected that the peak weekly hospitalization rate for COVID-19 in the 2025-2026 season will likely match or exceed that of the previous year, with moderate confidence intervals suggesting the highest burden occurring in January.1

This report provides an exhaustive examination of the status of the pandemic as of early 2026. It explores the virological characteristics of the dominant XFG variant, the specific pathophysiology driving the Long COVID crisis—including novel discoveries regarding fibrin amyloid microclots and neuroinflammation—and the efficacy of current therapeutic interventions. Furthermore, it analyzes the profound "shadow pandemic" of economic and labor market disruptions caused by the mass-disabling event of chronic Long COVID, which continues to challenge the resilience of the American healthcare and economic systems.

2. Virological Evolution and Genomic Surveillance

The SARS-CoV-2 virus continues to exhibit a high degree of evolutionary plasticity. The winter of 2025-2026 is defined by the displacement of earlier Omicron sublineages by a "swarm" of highly mutated variants, with the XFG lineage establishing dominance across the United States.

2.1 The Ascendance of Variant XFG

Genomic surveillance data as of January 2026 identifies XFG as the predominant variant nationwide, accounting for approximately 61% of sequenced cases.5 This variant, along with its sub-lineages such as XFG.14.1 (15%) and XFG.1 (5%), has effectively replaced the previously circulating JN.1 and KP.2 strains.5

The evolutionary success of XFG is attributed to a specific constellation of mutations that confer a moderate degree of immune escape. Phylogenetic analysis places XFG within the broader umbrella of JN.1-derived lineages, but it remains antigenically distinct enough to bypass the first line of antibody defense in individuals with hybrid immunity (immunity derived from both vaccination and prior infection).7

Table 1: Dominant and Monitoring SARS-CoV-2 Variants in the US (January 2026)


Variant Lineage

Estimated Prevalence

Evolutionary Characteristics

XFG

61%

Dominant strain; possesses mutations A475V and N487D which facilitate immune escape while maintaining ACE2 binding.8

XFG.14.1

15%

Sub-lineage of XFG showing similar antigenic properties.

XFG.1

5%

Minor circulating sub-lineage.

NB.1.8.1

<5% (Variable)

Retains high ACE2 affinity and humoral immune evasion; monitored for potential future dominance.8

LP.8.1

Declining

The target of the 2025-2026 vaccine formulation; now fading in prevalence due to XFG displacement.9

BA.3.2

Low

Limited outbreak potential currently due to limited ability to compete with NB.1.8.1.8

Source: Aggregated from Nebraska Med 5, WHO 6, and bioRxiv preprints.8

2.2 Mutation Profiles and Immune Escape Mechanisms

The specific mutations carried by XFG and its competitors provide insight into the virus's survival strategy. Research indicates that XFG and related variants like LF.7.9 demonstrate strong immune escape associated with specific amino acid substitutions in the Spike protein, specifically A475V and N487D.8

While these mutations enhance the virus's ability to evade neutralizing antibodies, they often come at a "fitness cost," such as reduced receptor-binding efficiency. However, compensatory adaptations have allowed XFG to maintain sufficient transmissibility to become dominant. In contrast, the variant NB.1.8.1 is being closely monitored because it has managed to retain high affinity for the ACE2 receptor (the virus's entry point into human cells) while simultaneously evading humoral immunity, supporting its potential for future dominance if XFG wanes.8

The antigenic distance between these new variants and the vaccines used in late 2025 is a critical concern. Studies utilizing antigenic cartography—a method of mapping the antibody responses to different viral strains—reveal that XFG is antigenically distant from the LP.8.1 strain used in the 2025-2026 vaccine formulation.10 This mismatch means that while the vaccine likely remains effective against severe disease, its ability to prevent infection is significantly reduced compared to a scenario where the vaccine and circulating virus are perfectly matched.

2.3 Viral Kinetics and Hospitalization Risks

The emergence of variants with "moderate immune escape" like XFG has tangible public health consequences. CDC scenario modeling projected that the emergence of such a variant could drive peak weekly hospitalization rates to between 6.7 and 9.5 per 100,000 population, compared to a lower range of 3.8–5.9 without such a variant.1

This modeling underscores that the volume of hospitalizations in 2026 is not solely a function of seasonal behavior or waning immunity, but is actively driven by the virus's genetic drift. Importantly, while XFG is more transmissible in the context of current population immunity, there is no evidence suggesting it is intrinsically more virulent (i.e., causing more severe disease per infection) than previous Omicron subvariants.12

3. Epidemiology of the 2025-2026 Winter Season

The epidemiology of COVID-19 in early 2026 is characterized by significant geographic heterogeneity and the confounding effects of co-circulating pathogens.

3.1 Transmission Dynamics and Reproductive Numbers

As of December 30, 2025, the effective reproductive number (Rt)—a key metric indicating whether an epidemic is growing (Rt > 1) or shrinking (Rt < 1)—showed that COVID-19 infections were growing or likely growing in 37 U.S. states.13

The geographic distribution of this growth is uneven. While some major population centers showed signs of stabilization, other regions experienced rapid acceleration in transmission.

Table 2: State-Level Transmission Trends (Rt Estimates, Dec 30, 2025)

State

Trend Classification

Rt Value (proxy)*

Vermont

Growing

>99.99 (High confidence of growth)

Oregon

Growing

99.98

South Dakota

Growing

99.90

North Dakota

Growing

91.30

New York

Likely Declining

19.73 (Low probability of growth)

Texas

Declining

0.90 (Rt < 1)

North Carolina

Declining

0.88 (Rt < 1)

Note: The "Rt Value" column in some datasets represents the probability that Rt > 1, or the estimated Rt itself. In this context, values like 0.88 and 0.90 represent the actual reproductive number, while values like 99.98 represent the probability percentage of epidemic growth..13

This data suggests that the wave of infection is moving across the country in a staggered fashion, likely influenced by regional variations in climate, indoor gathering patterns, and local immunity walls.

3.2 The "Syndemic" Context: Influenza and RSV

The burden on the healthcare system is amplified by the simultaneous circulation of Influenza and RSV. The 2025-2026 flu season has been complicated by the emergence of Influenza A (H3N2) subclade K, a "super flu" variant that has driven hospitalization surges in peer nations like the United Kingdom and Australia.2

Subclade K possesses seven gene changes on a key segment of the virus, altering its shape sufficiently to evade recognition by the immune system trained on older flu strains.3 While not necessarily causing more severe disease on a per-case basis, its rapid spread contributes to the overall respiratory viral load in the community.

Conversely, the outlook for RSV (Respiratory Syncytial Virus) is more stable. Hospitalization rates are projected to remain within 20% of the previous season's levels. A bright spot in the epidemiological data is the continued success of pediatric RSV immunizations (maternal vaccination and monoclonal antibodies), which have maintained high effectiveness in reducing infant hospitalizations.1

4. The Shadow Pandemic: Long COVID (PASC) Epidemiology

While the acute phase of the pandemic is now managed through established protocols, the chronic phase—Post-Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID—remains a pervasive and largely unmitigated public health crisis. By 2026, it is evident that Long COVID is a mass-disabling event with cumulative risks.

4.1 Prevalence Estimates and Demographics

Global analyses published through 2025 estimate the pooled prevalence of Long COVID at approximately 36% among those infected, although estimates vary based on study design and definitions.14 In the United States, data derived from electronic health records (EHR) suggests a diagnosis rate between 10% and 26% of adults and approximately 4% of children following a confirmed infection.16

Crucially, "prevalence" is not a static number. It is a dynamic accumulation of cases. A study of 192,651 residents found that the overall detected prevalence of Long COVID in the general population was 2.4 per 1,000, but this likely represents a significant undercount of undiagnosed cases.17

Table 3: Demographic Risk Factors for Long COVID (2025-2026 Findings)


Risk Factor

Odds Ratio / Association

Insight

Gender

OR 1.56 (Female)

Women are significantly more likely to develop PASC than men, potentially linked to autoimmune mechanisms.15

Vaccination Status

OR 2.09 (Unvaccinated)

Lack of vaccination doubles the risk, though breakthrough infections in vaccinated individuals still carry PASC risk.15

Age

Bimodal / Increasing

Risk increases with age (especially >65), but significant prevalence exists in working-age adults (30-59).16

Initial Severity

Positive Correlation

Hospitalization predicts higher PASC risk, yet the majority of PASC cases numerically come from mild acute infections due to the larger denominator.16

4.2 The Cumulative Risk of Reinfection

One of the most critical discoveries of the 2024-2025 research period is the debunking of the "natural immunity" safety net regarding chronic sequelae. Reinfections are not benign. Data from 2025 indicates a linear dose-response relationship between the number of SARS-CoV-2 infections and the risk of developing Long COVID.

In a monitored population, Long COVID prevalence increased from 9.1% after a single infection to 30.7% after three or more infections in unvaccinated individuals. A similar trend was observed in vaccinated cohorts, where prevalence rose from 10.6% to 25.4% after multiple infections.17 This finding has profound implications for public health policy, suggesting that a strategy of "letting the virus rip" results in a progressively more disabled population over time.

5. Pathophysiology: Unlocking the Mechanisms of Long COVID

Scientific understanding of Long COVID has advanced significantly by 2026, moving from descriptive symptom lists to the identification of concrete biological mechanisms. The condition is now understood as a multisystem dysregulation driven by three primary engines: viral persistence, coagulopathy (microclots), and neuroinflammation.

5.1 Viral Reservoirs and Persistence

A leading driver of chronic inflammation is the persistence of SARS-CoV-2 RNA and viral proteins in tissue reservoirs long after the acute infection has cleared from the respiratory tract. Biopsy and autopsy studies have identified viral debris in the gut, lymph nodes, and the central nervous system.18

This "ghost infection" engages the immune system in a perpetual war. The presence of viral RNA can trigger a chronic release of cytokines (inflammatory signaling molecules), leading to the systemic exhaustion observed in patients. This mechanism is particularly implicated in the gastrointestinal symptoms and new-onset metabolic disorders seen in Long COVID patients, as the virus may continue to replicate at low levels in the mucosal linings of the gut.18

5.2 The "Microclot" Hypothesis: Fibrin Amyloidosis

Perhaps the most significant breakthrough regarding the fatigue and exertion intolerance (Post-Exertional Malaise) characteristic of Long COVID is the confirmation of fibrin amyloid microclots.

Research has demonstrated that the SARS-CoV-2 Spike protein is amyloidogenic—it can cause the blood clotting protein fibrinogen to misfold into anomalous clots that are resistant to plasmin, the enzyme responsible for dissolving clots.20 Specifically, studies using purified coagulation components found that Spike685 amyloid fibrils (a specific segment of the spike protein) induce the formation of dense fibrin networks that exhibit marked resistance to fibrinolysis.21

These "fibrinaloids" circulate in the blood, trapping inflammatory molecules and mechanically blocking microcapillaries. This results in cellular hypoxia—tissue starvation of oxygen—even when a patient's macro-vascular oxygen levels (SpO2) appear normal. This explains the "air hunger" and crushing fatigue reported by patients; their blood is oxygenated, but the oxygen cannot reach the tissues through the clogged micro-vessels.20

Therapeutic investigations in 2025 have begun to focus on breaking these clots. Studies utilizing low-intensity focused ultrasound (LIFU), particularly at 150 kHz, have shown promise in fragmenting these amyloid microclots, especially when combined with microbubbles and thrombolytic agents like rtPA.20

5.3 Neuroinflammation and "Brain Fog"

The cognitive impairment often trivialized as "brain fog" has been mapped to specific neuro-biological changes. 2025 imaging studies using advanced Positron Emission Tomography (PET) have pinpointed widespread increases in AMPA receptor density in the brains of Long COVID patients.23

AMPA receptors are crucial for synaptic transmission and plasticity. Their upregulation is often a response to neuroinflammation and is linked to excitotoxicity, where over-stimulated neurons are damaged or die. This provides a measurable biological basis for the memory deficits, attentional failures, and executive dysfunction reported by millions. Furthermore, this neuroinflammation is often accompanied by the loss of smell (anosmia), which serves as a clinical marker for potential upstream neurological involvement.24 The cognitive deficits observed in severe cases are comparable to an acceleration of brain aging by several years.25

6. Systemic Sequelae: The Post-COVID Body

The impact of SARS-CoV-2 extends into a broad spectrum of organ-specific pathologies that persist or emerge months after infection.

6.1 Cardiovascular Consequences

Cardiologists in 2026 are managing a wave of "Post-COVID Heart" conditions. The virus is a potent vascular pathogen, capable of infecting endothelial cells and causing endotheliitis (inflammation of the blood vessel lining). Advanced PET/MRI imaging has detected persistent inflammation in the myocardium (heart muscle) and lungs of patients up to a year post-infection, even in those whose standard echocardiograms appear normal.26

This subclinical inflammation translates into severe risks. Meta-analyses of millions of patients indicate that Long COVID is associated with a drastically higher hazard ratio for myocarditis (HR 6.11), thromboembolic disorders (HR 3.12), and heart failure (HR 1.72) compared to non-infected controls.27 Alarmingly, the absolute number of thrombotic events (blood clots) in individuals over age 60 has doubled between 2020 and 2024, a trend that is visible regardless of vaccination status, suggesting that the vascular damage is a fundamental property of the infection itself rather than a modulation by the vaccine.28

6.2 Metabolic Dysregulation and New-Onset Diabetes

There is a confirmed causal link between COVID-19 and the development of diabetes mellitus. The virus attacks the pancreas via two pathways:

  1. Direct Cytotoxicity: SARS-CoV-2 infects pancreatic beta cells (which produce insulin) through the ACE2 receptor, leading to cell death.29

  2. Autoimmune Triggering: The systemic inflammation and specific cytokines like Interferon-gamma (IFN-γ) can induce insulin resistance and disrupt the protective role of regulatory T-cells (Tregs) within the pancreatic islets.31

This "diabetogenic" effect has led to a statistically significant rise in both Type 1 and Type 2 diabetes diagnoses in the months following infection, requiring a multidisciplinary approach involving endocrinologists to manage this new cohort of metabolic patients.33

7. Therapeutics: Progress and Setbacks

The medical community's effort to treat Long COVID has yielded both significant breakthroughs and disappointing failures by 2026.

7.1 The Metformin Breakthrough (Prevention)

One of the most robust findings to date is the utility of Metformin, a widely used diabetes medication, as a preventative agent against Long COVID. A large UK target trial emulation, analyzing data from over 600,000 patients and building on the results of the COVID-OUT randomized trial, found that initiating Metformin within 3 days of a COVID-19 diagnosis reduced the incidence of Long COVID by approximately 63% to 64% in overweight or obese adults.34

The mechanism of action appears to be distinct from glycemic control. Metformin exhibits potent anti-inflammatory properties and may inhibit viral replication via the mTOR pathway.35 This finding offers a cheap, globally available tool to reduce the future burden of chronic disease, provided it can be administered in the tight acute-phase window.

7.2 Failures in Drug Repurposing (Treatment)

In contrast, hopes that other existing antivirals or anti-inflammatories would cure established Long COVID have largely been dashed.

  • Paxlovid (Nirmatrelvir/Ritonavir): The NIH RECOVER initiative reported in late 2025 that a 15-day course of Paxlovid was generally ineffective at treating the somatic symptoms of Long COVID (shortness of breath, chest pain), although it showed minor efficacy for cognitive symptoms and fatigue in specific subgroups.36 It also failed to significantly prevent Long COVID in lower-risk populations.

  • Montelukast: This asthma medication, hypothesized to reduce respiratory inflammation, failed to shorten symptom duration in the ACTIV-6 randomized clinical trial.38

7.3 The Emerging Pipeline

The pipeline for 2026 offers renewed hope. PridCor Therapeutics has advanced a combination antiviral regimen (IMC-2) into Phase 2 trials following a successful case series that showed improvements in fatigue and dysautonomia.41 Additionally, the RECOVER initiative is pivoting toward treatments that address the biological roots of the disease, including Stellate Ganglion Blocks (to reset the autonomic nervous system) and GLP-1 agonists (for their anti-inflammatory and neuroprotective effects).42

8. Socioeconomic Impact: The Costs of Endemicity

The aggregation of millions of Long COVID cases has produced a macroeconomic shock that the U.S. economy is struggling to absorb. The "missing workers" phenomenon has altered the labor market structure.

8.1 Labor Market Disruptions

Economists at the Brookings Institution and other think tanks have identified Long COVID as a primary structural driver of the post-pandemic labor shortage. Data indicates that between 2 million and 4 million Americans are out of the workforce due to Long COVID.43

This absenteeism is not merely a temporary sick leave; it represents a semi-permanent reduction in the Labor Force Participation Rate. The economic burden of these lost wages is estimated at $170 billion to $230 billion annually in the US alone.43 When adjusting for the quality-adjusted life years (QALYs) lost and increased medical expenditures, the total cost could approach $3.7 trillion over the long term.44

The impact is visible in the Beveridge Curve—the relationship between unemployment and job vacancies. Between 2022 and 2024, the curve shifted outward, indicating a decrease in the efficiency of matching workers to jobs, partly due to the health-related friction introduced by Long COVID.45 Industries requiring high physical stamina or intense cognitive focus are disproportionately affected, as workers with "brain fog" or fatigue cannot maintain pre-infection productivity.46

8.2 Disability Insurance and Safety Nets

The Social Security Administration (SSA) has been inundated with disability claims related to Long COVID. While the SSA has managed to reduce the backlog of initial claims by 25% as of 2025, the system remains under intense pressure.47

Adjudicating these claims is difficult. The relapsing-remitting nature of Long COVID, combined with the lack of definitive biomarkers in standard clinical tests (standard blood panels do not show microclots), leads to high denial rates. However, updated guidance and the sheer volume of applicants are forcing a slow adaptation of disability criteria.48

9. Public Health Policy and Future Outlook

9.1 Vaccination Strategy and Mismatch

The FDA and CDC have adopted an annual vaccination cadence. For the 2025-2026 season, vaccines were updated to target the LP.8.1 lineage.9 However, the rapid emergence of XFG has created a "vaccine mismatch."

Current research suggests that while the LP.8.1-based vaccines induce strong neutralizing antibodies against the homologous strain, their efficacy against the antigenically distant XFG variant is reduced.10 Furthermore, the phenomenon of immune imprinting—where the immune system preferentially boosts antibodies against the strain it first encountered (the ancestral Wuhan strain)—may be limiting the breadth of protection offered by updated boosters.50 Despite this, vaccination remains a critical tool for preventing hospitalization and death.

9.2 Clinical Guidelines

In response to the complexity of Long COVID, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) and the CDC have released updated 2026 guidelines.49 These guidelines emphasize:

  • Symptom Validation: Clinicians must validate patient experiences even in the absence of objective lab findings.

  • Pacing: Strict adherence to energy conservation (pacing) to avoid Post-Exertional Malaise (PEM).

  • Holistic Management: Treating specific symptom clusters like dysautonomia (POTS) and mast cell activation rather than searching for a single "silver bullet".49

10. Conclusion

As of January 2026, the United States is living in the shadow of a pandemic that has not ended, but changed form. The acute threat of mass mortality has been replaced by the chronic threat of mass morbidity. The dominance of the XFG variant demonstrates the virus's relentless capacity for evolution, ensuring that reinfection remains a constant feature of American life.

The discovery of biological mechanisms such as fibrin amyloid microclots and viral reservoirs validates the suffering of millions and points the way toward targeted treatments. However, until these treatments are validated and widely available, the "Shadow Pandemic" of Long COVID will continue to exert a heavy toll on the nation's health and economy. The challenge for 2026 and beyond is to build a public health infrastructure that acknowledges and mitigates the long-term damage of a virus that is now a permanent resident of the human population.

Works cited

  1. CDC Predicts Possibility of Higher COVID-19 Hospitalizations for 2025-26 Season, accessed January 8, 2026, https://respiratory-therapy.com/disorders-diseases/infectious-diseases/coronavirus/cdc-higher-covid-19-hospitalizations/

  2. How Bad Will This Winter Be for Flu, COVID, RSV, and Measles?, accessed January 8, 2026, https://publichealth.jhu.edu/2025/virus-transmission-trends-winter-2025-26

  3. Mapped: 'Super flu' variant driving surge in cases, hospitalizations, accessed January 8, 2026, https://www.advisory.com/daily-briefing/2026/01/06/flu-update

  4. 2025-2026 Respiratory Disease Season Outlook | CFA: Qualitative Assessments - CDC, accessed January 8, 2026, https://www.cdc.gov/cfa-qualitative-assessments/php/data-research/season-outlook25-26.html

  5. What COVID-19 variants are going around in December 2025? - Nebraska Medicine, accessed January 8, 2026, https://www.nebraskamed.com/COVID/what-covid-19-variants-are-going-around

  6. COVID-19 variants | WHO COVID-19 dashboard - WHO Data, accessed January 8, 2026, https://data.who.int/dashboards/covid19/variants

  7. XFG has been designated a SARS-CoV-2 variant under monitoring (VUM) with increasing proportions globally. - World Health Organization (WHO), accessed January 8, 2026, https://www.who.int/docs/default-source/coronaviruse/25062025_xfg_ire.pdf

  8. Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1, accessed January 8, 2026, https://www.biorxiv.org/content/10.1101/2025.04.30.651462v1

  9. Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19, accessed January 8, 2026, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval

  10. Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination - NIH, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12407627/

  11. Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination | mBio - ASM Journals, accessed January 8, 2026, https://journals.asm.org/doi/10.1128/mbio.02901-25

  12. SARS-CoV-2 Omicron variant - Wikipedia, accessed January 8, 2026, https://en.wikipedia.org/wiki/SARS-CoV-2_Omicron_variant

  13. Current Epidemic Trends (Based on Rt) for States | CFA: Modeling and Forecasting | CDC, accessed January 8, 2026, https://www.cdc.gov/cfa-modeling-and-forecasting/rt-estimates/index.html

  14. More than one-third of individuals with COVID-19 experience long COVID, accessed January 8, 2026, https://www.eatg.org/hiv-news/more-than-one-third-of-individuals-with-covid-19-experience-long-covid/

  15. Studies show how common long COVID is globally and in teens - CIDRAP, accessed January 8, 2026, https://www.cidrap.umn.edu/covid-19/studies-show-how-common-long-covid-globally-and-teens

  16. RECOVER Research Update: June 2025, accessed January 8, 2026, https://recovercovid.org/news/recover-research-update-june-2025

  17. Long COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium in the Metropolitan Area of Barcelona: Persistent and Transient Symptoms - NIH, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12474489/

  18. Advances in Understanding Long COVID: Pathophysiological Mechanisms and the Role of Omics Technologies in Biomarker Identification, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12436531/

  19. Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID - PMC, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12568064/

  20. Low-intensity ultrasound lysis of amyloid microclots in a lab-on-chip model - Frontiers, accessed January 8, 2026, https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1604447/full

  21. SARS-CoV-2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis | Biochemistry - ACS Publications, accessed January 8, 2026, https://pubs.acs.org/doi/10.1021/acs.biochem.5c00550

  22. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications - Portland Press, accessed January 8, 2026, https://portlandpress.com/biochemj/article/479/4/537/230829/A-central-role-for-amyloid-fibrin-microclots-in

  23. Scientists finally reveal what's behind long COVID's mysterious brain fog | ScienceDaily, accessed January 8, 2026, https://www.sciencedaily.com/releases/2025/10/251006051127.htm

  24. From Smell Loss to Brain Fog: Unpacking the Long COVID Puzzle - Stanford Medicine, accessed January 8, 2026, https://med.stanford.edu/medicine/news/current-news/standard-news/long-covid-care-2025.html

  25. Persistence of Cognitive Difficulties in Adults Three Years After COVID-19 Infection - MDPI, accessed January 8, 2026, https://www.mdpi.com/2673-8112/5/9/153

  26. Long COVID May Cause Long-Term Changes in the Heart and Lungs and May Lead to Cardiac and Pulmonary Diseases | Mount Sinai - New York, accessed January 8, 2026, https://www.mountsinai.org/about/newsroom/2025/long-covid-may-cause-long-term-changes-in-the-heart-and-lungs-and-may-lead-to-cardiac-and-pulmonary-diseases

  27. Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis, accessed January 8, 2026, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1450470/full

  28. Long COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium in the Metropolitan Area of Barcelona: Persistent and Transient Symptoms - MDPI, accessed January 8, 2026, https://www.mdpi.com/2076-393X/13/9/905

  29. New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review, accessed January 8, 2026, https://pubmed.ncbi.nlm.nih.gov/40326310/

  30. The Intersection of SARS-CoV-2 and Diabetes - MDPI, accessed January 8, 2026, https://www.mdpi.com/2076-2607/13/6/1390

  31. Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views - Frontiers, accessed January 8, 2026, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1737894/full

  32. Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12756089/

  33. New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review, accessed January 8, 2026, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2492211

  34. Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study - Oxford Academic, accessed January 8, 2026, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf429/8244943

  35. Metformin may reduce risk of long COVID by 64% in overweight or obese adults | CIDRAP, accessed January 8, 2026, https://www.cidrap.umn.edu/covid-19/metformin-may-reduce-risk-long-covid-64-overweight-or-obese-adults

  36. Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia | PLOS Medicine - Research journals, accessed January 8, 2026, https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004711

  37. RECOVER Research Update: December 2025, accessed January 8, 2026, https://recovercovid.org/news/recover-research-update-december-2025

  38. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial - PubMed Central, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11581631/

  39. Asthma Drug Shows No Benefit for Mild to Moderate COVID-19, Study Finds, accessed January 8, 2026, https://medschool.duke.edu/news/asthma-drug-shows-no-benefit-mild-moderate-covid-19-study-finds

  40. Montelukast didn't cut time to COVID symptom relief in clinical trial - CIDRAP, accessed January 8, 2026, https://www.cidrap.umn.edu/covid-19/montelukast-didnt-cut-time-covid-symptom-relief-clinical-trial

  41. PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program, accessed January 8, 2026, https://www.biospace.com/press-releases/pridcor-therapeutics-advances-shield-study-through-dual-regulatory-and-scientific-milestones-with-peer-reviewed-publication-and-fda-ind-exemption-for-long-covid-program

  42. RECOVER's 2nd Round of Long COVID Clinical Trials Shows Progress... and Limitations - Health Rising, accessed January 8, 2026, https://www.healthrising.org/blog/2025/10/10/recover-tlc-long-covid-promise-limitations/

  43. New data shows long Covid is keeping as many as 4 million people out of work | Brookings, accessed January 8, 2026, https://www.brookings.edu/articles/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/

  44. Long COVID takes $1 trillion global economic toll each year, analysis suggests | CIDRAP, accessed January 8, 2026, https://www.cidrap.umn.edu/covid-19/long-covid-takes-1-trillion-global-economic-toll-each-year-analysis-suggests

  45. How Have U.S. Workers Fared in a Labor Market Reshaped by the Pandemic? - Federal Reserve Bank of St. Louis, accessed January 8, 2026, https://www.stlouisfed.org/on-the-economy/2025/aug/how-us-workers-fared-labor-market-reshaped-pandemic

  46. The Prevalence and Challenge of Long COVID: Implications for the Workforce, accessed January 8, 2026, https://extension.missouri.edu/publications/mp1000

  47. Social Security Disability (SSD) Wait Times: a 2025 Study - Hiller Comerford, accessed January 8, 2026, https://www.hillercomerford.com/insights/ssd-wait-times-case-study/

  48. Long COVID: A Guide for Health Professionals on Providing Medical Evidence for Social Security Disability Claims, accessed January 8, 2026, https://www.ssa.gov/disability/professionals/documents/EN-64-128.pdf

  49. Long COVID Resources - American Academy of Physical Medicine and Rehabilitation, accessed January 8, 2026, https://www.aapmr.org/advocacy/current-priorities/long-covid-pasc/long-covid-resources

  50. Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination | ESWI, accessed January 8, 2026, https://eswi.org/education-hub/antibody-responses-sars-cov-2-variants-lp81-lf71-nb181-xfg-and-ba32-following-kp2

  51. Long COVID Clinical Guidance - CDC, accessed January 8, 2026, https://www.cdc.gov/long-covid/hcp/clinical-guidance/index.html

Comments

bottom of page